1. Home
  2. LEGN vs ELP Comparison

LEGN vs ELP Comparison

Compare LEGN & ELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • ELP
  • Stock Information
  • Founded
  • LEGN 2014
  • ELP 1954
  • Country
  • LEGN United States
  • ELP Brazil
  • Employees
  • LEGN N/A
  • ELP N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • ELP Electric Utilities: Central
  • Sector
  • LEGN Health Care
  • ELP Utilities
  • Exchange
  • LEGN Nasdaq
  • ELP Nasdaq
  • Market Cap
  • LEGN 5.4B
  • ELP 5.5B
  • IPO Year
  • LEGN 2020
  • ELP 1997
  • Fundamental
  • Price
  • LEGN $34.00
  • ELP $9.13
  • Analyst Decision
  • LEGN Strong Buy
  • ELP
  • Analyst Count
  • LEGN 12
  • ELP 0
  • Target Price
  • LEGN $77.09
  • ELP N/A
  • AVG Volume (30 Days)
  • LEGN 2.0M
  • ELP 301.8K
  • Earning Date
  • LEGN 08-08-2025
  • ELP 08-06-2025
  • Dividend Yield
  • LEGN N/A
  • ELP 6.37%
  • EPS Growth
  • LEGN N/A
  • ELP 31.95
  • EPS
  • LEGN N/A
  • ELP 0.17
  • Revenue
  • LEGN $728,303,000.00
  • ELP $4,033,509,015.00
  • Revenue This Year
  • LEGN $65.49
  • ELP N/A
  • Revenue Next Year
  • LEGN $53.76
  • ELP $5.55
  • P/E Ratio
  • LEGN N/A
  • ELP $12.82
  • Revenue Growth
  • LEGN 112.46
  • ELP 6.92
  • 52 Week Low
  • LEGN $27.34
  • ELP $5.72
  • 52 Week High
  • LEGN $60.87
  • ELP $9.28
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 53.16
  • ELP 63.05
  • Support Level
  • LEGN $33.84
  • ELP $8.76
  • Resistance Level
  • LEGN $35.29
  • ELP $9.28
  • Average True Range (ATR)
  • LEGN 1.96
  • ELP 0.16
  • MACD
  • LEGN 0.24
  • ELP -0.01
  • Stochastic Oscillator
  • LEGN 52.16
  • ELP 73.21

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About ELP Companhia Paranaense de Energia (COPEL) (each representing one Unit consisting one Common Share and four non-voting Class B Preferred Shares)

Cia Paranaense De Energia Copel is engaged in the areas of generation, transmission, commercialization and distribution of energy. It operates a comprehensive and effective electrical system with its own generating plants, transmission lines, substations, electrical lines and grids of the distribution system. The company's reportable segments include Power generation and transmission, Power distribution, GAS, Power sale, Holding and Services. Majority of its revenue is generated from the Power generation and transmission segment under which it produces electricity from hydraulic, wind, and thermal projects and provides services of transmission and transformation of electric power and other related services.

Share on Social Networks: